Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + capmatinib + enfortumab vedotin (Roche)
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen consists of erlotinib (Tarceva), capmatinib (Tabrecta), and enfortumab vedotin (Padcev). Erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Capmatinib is a selective inhibitor of the MET receptor tyrosine kinase. Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, which delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) directly to cancer cells. This specific combination is being evaluated in a personalized medicine context, such as the iCAGES-guided therapy study (NCT03535623), where treatments are selected based on the genomic and immunohistochemical profile of a patient's tumor to improve survival outcomes in advanced cancers.
- Other names
- Tarceva + capmatinib + Padcev
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)MET (Mesenchymal-epithelial transition factor receptor)PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on erlotinib + capmatinib + enfortumab vedotin (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + capmatinib + enfortumab vedotin (Roche).